No Data Yet
Abbott Laboratories received FDA and CE Mark clearance for its Amplatzer Piccolo Delivery System for premature infants, while also announcing a 6.8% dividend increase to US$0.63 per share.
Abbott announced on December 18, 2025, that it received FDA and CE Mark approval for its Amplatzer Piccolo Delivery System, designed to treat a heart defect in premature infants affecting approximately 20% of that population.
Parnassus Value Equity Fund endorsed Abbott Laboratories in its Q3 2025 investor letter, citing durable growth potential after the stock gained 10.93% over the last 52 weeks.
Edgewell Personal Care's (EPC) operating margin fell by 4.5 percentage points, signaling underperformance, while Abbott Laboratories (ABT) shows strength with 9.6% annual EPS growth.
Haemonetics (HAE) was downgraded to 'Hold' by Needham, citing intensified competition from Abbott and Cordis in the vascular closure device market.
The global blood glucose monitor market is projected to expand to $25.4 billion by 2030, growing at a 9.1% compound annual growth rate, driven by a rising diabetes prevalence and technological advancements.
Abbott Laboratories receives a Zacks Rank #4 (Sell) rating as its stock declined 2.4% over the past month, underperforming the S&P 500, despite forecasts for 10% annual earnings growth.
A comparative analysis finds Prestige Consumer Healthcare (PBH) to be a better value stock than Abbott (ABT), citing PBH's lower forward P/E ratio of 13.54 versus ABT's 24.64.
Abbott Laboratories is executing a $23 billion acquisition of diagnostics firm Exact Sciences to enter the cancer screening market. The move occurs as the company manages a significant medical device correction for its FreeStyle Libre glucose sensors and faces ongoing litigation.
Abbott has expanded its Lingo continuous glucose monitor (CGM) to the Android platform, signaling a strategic push into the mass-market consumer wellness sector beyond its traditional medical device focus. This move aims to capitalize on growing preventative health trends but coincides with significant operational headwinds from a device correction in its flagship FreeStyle Libre CGM line.
Abbott Laboratories showcases a strong balance sheet with reduced debt and high interest coverage, presenting a stable profile amid a volatile healthcare sector focused on obesity drugs and policy shifts.
Abbott has raised its quarterly dividend to $0.63 per share, marking 54 consecutive years of increases. The move highlights the company's financial stability and commitment to shareholder returns amid broader market discussions on the reliability of dividend strategies.
Medtronic has received two significant U.S. Food and Drug Administration (FDA) clearances for its Hugo robotic-assisted surgery (RAS) system and its MiniMed 780G diabetes management system, strengthening its competitive stance in the high-growth med-tech sector.
Abbott Laboratories is facing potential liabilities of $4 billion from lawsuits alleging its Similac preemie formula is linked to a dangerous infant disease. The company is now lobbying for federal legislation that would block state-level lawsuits and create a centralized distribution system, threatening to pull the product if its demands are not met.
Mixed Q3 earnings in the medical devices sector triggered sharp, divergent stock reactions. Neogen Corporation (NEOG) soared on a revenue beat, while Baxter International (BAX) tumbled after missing analyst expectations, highlighting a highly selective investor market.